Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06628661 | Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion | recruiting | — | 3,000 | Chang Gung Memorial HospitalOTHER | 1 | Nov 20, 2024 |
| clinicaltrials |
| NCT06694636 | Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 5 | Zhongda HospitalOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05072041 | Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma | recruiting | N/A | 150 | Next Biomedical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05887661 | Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06682377 | Radiofrequency Ablation Using Combined RF Energy Delivery Mode and Octopus Electrodes for Hepatocellular Carcinoma(SM-OCT-01) | active not recruiting | N/A | 159 | Seoul National University HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06461624 | Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06595108 | Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma(A-BEST) | recruiting | N/A | 33 | Yonsei UniversityOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06669377 | TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. | recruiting | — | 444 | Zhongda HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06647264 | A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery | enrolling by invitation | — | 1,500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06639971 | Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC(RIO-HCC) | not yet recruiting | — | 500 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643533 | Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) | not yet recruiting | — | 15 | Fujian Provincial HospitalOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06569498 | Neoadjuvant Triple Therapy for Resectable HCC(TALENP001) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06602011 | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04195503 | Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | enrolling by invitation | N/A | 10 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | recruiting | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06592612 | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment | not yet recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06593964 | TACE With Thermosensitive Nanogel Versus Embosphere for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601231 | To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.(ADRENALIN) | recruiting | — | 1,000 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602986 | Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma | not yet recruiting | N/A | 96 | Pak Emirates Military HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT06581315 | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma | recruiting | N/A | 204 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06561399 | Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) | recruiting | — | 28 | Fujian Provincial HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06559761 | Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research | recruiting | — | 500 | Chinese PLA General HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06550921 | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma | recruiting | N/A | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06519578 | Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 1,115 | RenJi HospitalOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab(CPAB) | not yet recruiting | Phase 2 | 40 | Chulalongkorn UniversityOTHER | 0 | Aug 2, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06524466 | Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2024source: clinicaltrials